华大基因: 第四届董事会第六次会议决议公告

Group 1 - The board of directors of Shenzhen BGI Genomics Co., Ltd. confirmed the authenticity and completeness of the 2025 semi-annual report, stating it accurately reflects the company's financial status and operational results [1][2] - The board meeting was conducted via email, with all directors notified of the meeting details, and the meeting was compliant with relevant laws and regulations [1] - The company approved a capital increase of 22 million Saudi Riyals (approximately 42 million RMB) to its associate company, Genalive Medical Company, which will raise Genalive's registered capital from 90.5 million to 134.5 million Saudi Riyals [2] Group 2 - After the capital increase, BGI Almanahil Health for Medical Services will maintain a 50% equity stake in Genalive, and the consolidation scope of the company's financial statements will not change [2] - The board's decision on the capital increase was previously reviewed and approved by the audit committee and independent directors [2][3]